NEW YORK, April 23-Lynx Therapeutics and Wilex AG will work together to identify genes regulated by Wilex' lead compound for renal cell carcinoma, the companies said today.
Lynx will use its Massively Parallel Signature Sequencing system to analyze gene expression differences in samples treated with the Wilex compound.
Wilex CEO Olaf Wilhelm said in a statement that the Lynx technology may reveal markers that can predict patient response to drug therapy, making it possible to identify those patient subpopulations most likely to benefit from the new drug. The process may also reveal additional therapeutic targets for combination drug treatment.
Lynx will receive service payments from Wilex.
The Wilex compound, WX-G250, is designed to induce antibody dependent cellular cytoxicity in renal cell carcinomas. It is currently in phase II clinical trials.
Renal cell carcinoma is the tenth most common cancer in the Unites States, and causes more than 12,000 deaths annually.
Wilex, a biopharmaceutical company based in Munich, focuses on treatments for cancer.